制药工业
药物开发
药物发现
过程(计算)
药品
过程开发
风险分析(工程)
计算机科学
损耗
数据科学
业务
医学
过程管理
药理学
生物信息学
生物
操作系统
牙科
作者
Kit‐Kay Mak,Mallikarjuna Rao Pichika
标识
DOI:10.1016/j.drudis.2018.11.014
摘要
Artificial intelligence (AI) uses personified knowledge and learns from the solutions it produces to address not only specific but also complex problems. Remarkable improvements in computational power coupled with advancements in AI technology could be utilised to revolutionise the drug development process. At present, the pharmaceutical industry is facing challenges in sustaining their drug development programmes because of increased R&D costs and reduced efficiency. In this review, we discuss the major causes of attrition rates in new drug approvals, the possible ways that AI can improve the efficiency of the drug development process and collaboration of pharmaceutical industry giants with AI-powered drug discovery firms.
科研通智能强力驱动
Strongly Powered by AbleSci AI